Skip to main content
. 2023 Jan 9;15(2):260–269. doi: 10.21037/jtd-22-1011

Figure 1.

Figure 1

Kaplan-Meier estimates of (A) PFS and (B) OS according to the line of ICI therapy (first-line vs. second- or further line). Kaplan-Meier estimates of (C) PFS and (D) OS according to ICI regimen (monotherapy vs. combination therapy). Kaplan-Meier estimates of (E) PFS and (F) OS according to EGFR/ALK/KRAS/MET mutation status [EGFR/ALK/KRAS/MET alterations (mutant group) vs. wild type (non-mutant group)]. PFS, progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; ICI, immune checkpoint inhibitors; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten rat sarcoma; MET, mesenchymal-epithelial transition factor.